Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Reexamination Certificate
2006-01-25
2008-11-11
Duffy, Patricia A (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
C424S243100
Reexamination Certificate
active
07449189
ABSTRACT:
StaphylococcalandEnterrococcalglycoconjugate vaccines are disclosed for use in preventing or treating bacterial infection in an immune-compromised individual. Such vaccines contain an immunocarrier and a conjugate of a polysaccharide or glycopeptide surface antigen from a clinically-significant bacterial strain. The vaccines can be used for active protection in immune-compromised individuals who are to be subjected to conditions that place them at immediate risk of developing a bacterial infection, as would be case in the context of a catheterization or a surgical procedure.
REFERENCES:
patent: 5747024 (1998-05-01), Grabstein et al.
patent: WO 98/10788 (1998-03-01), None
Vaccine Weekly, Sep. 30, 1996, p. 10.
Fattom et al (Vaccine, 13(14):1288-1293, 1995.
Shinefield et al (New England Journal of Medicine 346(7):491-496, Feb. 14, 2002.
Naso et al (Advances in Experimental Medicine and Biology, 397:133-140, 1996.
A. Fattom et al.: ‘Results from an efficacy study of Nabi® StaphVAX® (Staphylococcus aureus capsular polysaccharide (CP) conjugate vaccine) in hemodialysis patients’, Abstracts of Papers American Chemical Society, 2001, vol. 221, No. 1-2, p. BIOT 45.
D. Gury and T. Mclain, Press Release, “Nabi Reports Successful Reduction in S. Aureus Bacteremias at Interscience Conference on Antimicrobial Agents and Chemotherapy(ICACC),” Sep. 19, 2000, Toronto, Canada.
Fattom et al., “Effect of Conjugation Methodology, Carrier Protein, and Adjuvants on the Immune Response to Staphylococcus Aureus Capsular Polysaccharides,” Elsevier Science Ltd., Vaccine, vol. 13, No. 14, pp. 1288-1293, 1995.
Fattom et al., “Results From an Efficacy Study of Nabi® StaphVAX® (Staphylococcus Aureus Capsular Polysaccharide (CP) Conjugate Vaccine) in Hemodialysis Patients,” Abstracts of Papers American Chemical Society, vol. 221, No. 1-2, p. 45, 2001.
Fattom et al., “Staphylococcal Vaccines: A Realistic Dream,” Annals of Medicine, Finnish Medical Society, vol. 28, No. 1, pp. 43-46, 1996.
Fattom et al. “Staphylococcus Aureus Vaccination for Dialysis Patients—An Update,” Advances in Renal Replacement Therapy, vol. 3, No. 4, 1996.
Naso et al., “Polysaccharide Conjugate Vaccines for the Prevention of Gram-Positive Bacterial Infections,” Advances in Experimental Medicine and Biology, vol. 397, pp. 133-140, 1996.
Welch et al., “Safety and Immunogenicity of Staphylococcus Aureus Type 5 Capsular Polysaccharide-Pseudomonas Aeruginosa Recombinant Exoprotein A Conjugate Vaccine in Patients on Hemodialysis,” Journal of the American Society of Nephrology, vol. 7, pp. 247-253, 1996.
Nabi Biopharmaceuticals Press Release, “Nabi Biopharmaceuticals Announces Results of StaphVAX® Confirmatory Phase III Clinical Trial,” Nov. 1, 2005, 2 pages.
Search Report.
Shinefield, M.D., Henry et al., “Use of aStaphylococcus aureusConjugate Vaccine in Patients Receiving Hemodialysis”,N. Engl. J. Med., vol. 346, No. 7, pp. 491-496, Feb. 14, 2002.
Ambrosino et al., “Response toHaemophilus influenzaeType B Conjugate Vaccine in Children Undergoing Splenectomy,” Journal of Pediatric Surgery 27(8):1045-1048 (Aug. 1992).
Campbell et al., “Immunogenicity of a 24-ValentKlebisellaCapsular Polysaccharide Vaccine and an Eight-ValentPseudomonasO-Polysaccharide Conjugate Vaccine Administered to Victims of Acute Trauma,” Clinical Infectious Diseases, 23:179-181 (1996).
O'Brien et al., “Safety and Immunogenicity of Haptavalent Pneumococcal Vaccine Conjugated to CRM197Among Infacts With Sickle Cell Disease,” Pediatrics 106(5):965-972 (Nov. 2000).
Robbins and Schneerson, “Polysaccharide-Protein Conjugates: A New Generation of Vaccines,” The Journal of Infectious Diseases 161:821-832 (1990).
Shinefiled and Black, “Efficacy of pneumococcal conjugate vaccines in large scale field trials,” Podiatr Infect Dis J. 19:394-397 (2000).
Sood et al., “Capsular polysaccharide-protein conjugate vaccines,” Drug Discovery Today 1(9):381-387 (Sep. 1996).
The Dictionary of Immunology, Herbert et al. eds, Academic Press, 1995—Definition of Vaccine.
Fattom Ali I.
Naso Robert B.
Duffy Patricia A
Foley & Lardner LLP
NABI Biopharmaceuticals
LandOfFree
Glycoconjugate vaccines for use in immune-compromised... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Glycoconjugate vaccines for use in immune-compromised..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glycoconjugate vaccines for use in immune-compromised... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4040966